Abstract
Sera of vaccines were assessed by surrogate virus neutralization tests for their capacity to neutralize the SARS-CoV-2 Delta variant. Homologous prime-boost immunization with Moderna’s Spikevax as well as heterologous immunization with AstraZeneca’s Vaxzevria followed by Moderna’s Spikevax were identified as highly potent vaccination regimens for the induction of Delta-neutralizing antibodies.
Keywords: SARS-CoV-2; antibodies; vaccination.
All Keywords
【저자키워드】 antibodies, SARS-CoV-2, vaccination, 【초록키워드】 Vaccine, vaccination, Neutralizing antibodies, delta variant, immunization, sera, virus neutralization test, AstraZeneca, Heterologous, Moderna, heterologous immunization, neutralization tests, regimen, followed by, neutralize, the SARS-CoV-2, were assessed, 【제목키워드】 neutralizing antibody, vaccination, delta variant, homologous, Heterologous, the SARS-CoV-2,
【저자키워드】 antibodies, SARS-CoV-2, vaccination, 【초록키워드】 Vaccine, vaccination, Neutralizing antibodies, delta variant, immunization, sera, virus neutralization test, AstraZeneca, Heterologous, Moderna, heterologous immunization, neutralization tests, regimen, followed by, neutralize, the SARS-CoV-2, were assessed, 【제목키워드】 neutralizing antibody, vaccination, delta variant, homologous, Heterologous, the SARS-CoV-2,
{{{ 추상적인 }}}
백신의 혈청은 SARS-CoV-2 Delta 변이체를 중화시키는 능력에 대해 대리 바이러스 중화 테스트에 의해 평가되었습니다. Moderna의 Spikevax를 사용한 동종 프라임-부스트 면역과 AstraZeneca의 Vaxzevria에 이어 Moderna의 Spikevax를 사용한 이종 면역은 Delta-중화 항체 유도를 위한 매우 강력한 백신 요법으로 확인되었습니다.
{{ 키워드: }} SARS-CoV-2; 항체; 백신 접종.